Here’s a question most startup founders never ask: what if the most valuable thing you’ve built doesn’t need a sales team, a supply chain, or a single new hire to generate revenue?
For most founders, the path to revenue runs through growth. More customers means more support staff. More product means more engineers. More markets means more headcount. It’s the only model most people know.
But there’s a parallel path — one that the most capital-efficient founders are starting to take seriously in 2026, as capital efficiency becomes the new gold standard and investors expect startups to do more with less, proving sustainable traction before accessing large rounds.
That path is IP licensing. And if you’ve built something genuinely innovative, it may be the most overlooked revenue channel in your entire business.
I’m Rand Brenner. I’ve spent 35 years structuring licensing deals across entertainment, consumer products, MedTech, and digital markets. I’ve watched founders discover — sometimes by accident — that the IP sitting in their patent portfolio or trade secret documentation was worth more in recurring royalties than their entire product revenue line. Here’s how to find out if yours is too.
Want to know if your IP is licensable right now? Let’s talk through your specific situation — free, 15 minutes. Schedule a Strategy Call →
Why 2026 Is the Right Moment to Think About This
The non-dilutive funding conversation has exploded in 2026. In 2026’s tighter VC climate — with rate pressure and longer fundraising cycles pushing founders to protect their cap tables — non-dilutive funding has become a smart first move to get a business off the ground.
Revenue-based financing is growing at 62%+ annually and reached $9.77 billion in market volume in 2025. The SBIR/STTR program distributes $4+ billion annually in non-dilutive grants. Founders are stacking grants, cloud credits, RBF lines, and government programs to stay equity-free as long as possible.
All of that is real. But there’s a non-dilutive revenue source that almost nobody in these conversations talks about: royalty income from licensing your IP to companies that want to use it.
The difference between licensing royalties and every other non-dilutive option? Royalty income isn’t capital you pay back. It isn’t a grant you compete for. It’s revenue — recurring, contractual revenue — generated by your IP being used in the market by someone else. It doesn’t require you to scale. It doesn’t require you to hire. And it doesn’t dilute your cap table by a single share.
Here’s how it works, and how to know if your startup is sitting on it.
What IP Licensing Actually Looks Like for a Startup
Let’s get concrete. IP licensing means granting another company the right to use your technology, brand, process, or content — in exchange for a royalty payment tied to their commercial use of it.
The key word is use. You keep ownership. You grant access. They pay you for it.
In practice, this can look like:
- A larger company in your industry paying you a percentage of revenue from products that incorporate your patented process
- A company in an adjacent industry paying you an annual flat fee plus per-unit royalties to white-label your algorithm or software capability
- A regional partner in a market you haven’t entered paying you for exclusive rights to commercialize your technology in their geography
- A competitor paying you to avoid an infringement claim — structured as a licensing agreement rather than a lawsuit
None of these require you to build more product. None of them require you to hire. The licensee does the selling, the manufacturing, the distribution, and the customer support. You collect a royalty check tied to their performance.
The business model that makes ARM Holdings worth over $50 billion isn’t about building chips. It’s about building IP and licensing it to everyone who does. Qualcomm generates billions in annual royalty revenue largely independent of its own chip sales. You don’t need their scale. You need their mindset.
The Three Questions That Determine If Your IP Is Licensable
Not every startup has IP worth licensing right now. But far more do than realize it. Here are the three questions that tell you where you stand:
1. Does someone else benefit from having access to what you’ve built?
This seems obvious, but founders often underestimate how broadly “someone else” applies. You’re looking for companies that would benefit from using your technology, process, or content in their own products or operations — companies that aren’t your direct customers and may not even be in your primary market.
An AI startup with a predictive maintenance algorithm built for manufacturing might find that its most valuable licensing partner isn’t a factory — it’s an equipment manufacturer who wants to embed predictive capabilities into their product line. A MedTech startup with a patented sensor technology built for hospitals might find that its best licensing conversation is with a consumer wearables company.
The question is never just “who uses this now?” It’s “who else could use this, and what would it be worth to them?”
2. Is there a meaningful cost or risk for that company to build it themselves?
Licensing deals happen when the build-vs-buy calculation favors buying access. If another company could replicate your innovation in three months with a small engineering team, the licensing conversation is short. If it would take them two years, $5 million in R&D, and still land them in patent infringement territory, the licensing conversation gets very interesting very quickly.
Your IP is most licensable when there’s a meaningful barrier to replication — either because the technical complexity is high, the patent protection is broad, or the time-to-market cost of building from scratch is prohibitive.
3. Do you have some form of IP protection — or could you establish one quickly?
Licensing deals require something to license. That can be a patent, a trade secret, a registered copyright, a proprietary dataset, or even a well-documented process with demonstrable competitive advantage. It doesn’t have to be a granted patent — “patent pending” status, trade secret documentation, and copyright registration are all sufficient to initiate licensing conversations.
If you answered yes to all three, you have the foundation for a licensing strategy. The next question is which of your IP assets to lead with.
The Four Licensing Models That Generate Revenue Without Scaling
Each of these structures generates recurring royalty income without requiring you to grow your team, build more product, or enter new markets yourself.
1. Field-of-Use License
You grant one company the right to use your IP exclusively within a specific application domain — healthcare diagnostics, for example — while retaining full rights in every other field. The licensee pays you a royalty on their revenue from that application. You can simultaneously license the same core IP to a different company in a different field.
This is the model that lets you monetize the same technology multiple times over. One AI startup we work with licensed its demand forecasting algorithm to a retail company in one field-of-use agreement and to a logistics company in another. Same IP, two separate royalty streams, no operational overlap.
2. Regional Exclusive License
You grant one company exclusive rights to commercialize your IP in a defined geographic territory — a country, a region, a continent — while retaining all rights everywhere else. Regional partners are often willing to pay a meaningful upfront fee for exclusivity in their market, plus ongoing royalties tied to their sales performance.
This works especially well for IP that solves a problem with different regional competitive dynamics — where the incumbent players vary by market and a local partner has distribution advantages you don’t.
3. White-Label / OEM License
You allow another company to deploy your technology under their own brand, either as a standalone product or as an embedded component of theirs. They handle all sales, marketing, and customer relationships. You receive a per-unit royalty or a percentage of revenue.
This is particularly effective for software platforms, AI capabilities, and proprietary processes where the underlying technology is more valuable as an ingredient than as a finished product. The licensee gets a capability they couldn’t easily build. You get revenue without touching their customer.
4. Technology Licensing with Performance Milestones
You structure the deal around your licensee hitting defined commercial targets — revenue thresholds, unit volumes, market penetration benchmarks — with royalty rates and payment structures that adjust accordingly. This aligns your income with the licensee’s success and gives them flexibility in the early stages of commercialization.
The key protections you must include: minimum royalty guarantees so you’re not left with nothing if they underperform, reversion rights so you can reclaim the license if they miss milestones without a cure period, and audit rights so you can verify their royalty calculations independently.
What This Looks Like in Practice
Let me walk you through the pattern we see consistently — not a single client story, but the sequence of events that plays out across different industries and different types of IP.
A company builds something that solves a specific problem in their primary market. They’re generating revenue from direct customers, but the business requires constant selling, onboarding, and support. The IP that powers the product — the patent, the algorithm, the proprietary process — sits in the background, doing its job but not being actively monetized beyond the product itself.
When we do an IP review with these companies, the conversation usually goes the same way. We ask: who else has the same problem your core technology solves? Not your customers — the companies whose customers have that problem. And then: what would it cost a company in an adjacent industry to build this capability themselves, starting from scratch?
That second question is where the licensing conversation opens up. If the answer is “significant investment and 18 months of R&D,” the field-of-use license conversation gets serious fast. The adjacent company doesn’t want to spend that time and money. They want access — and they’re willing to pay a royalty for it.
The result isn’t always a fast close. Licensing deals take time — typically 60 to 120 days from first conversation to signed agreement, sometimes longer with large enterprise partners who have procurement processes. But when they close, the economics look different from anything else in the business. No new headcount tied to the revenue. No support infrastructure. No cost of goods beyond the IP that already exists.
That’s the model. The company that owns the IP keeps building its primary business. The licensee handles commercialization in their market. The royalty arrives quarterly — recurring, contractual, growing as the licensee’s sales grow.
Zero new hires. Zero additional product development. Zero new infrastructure. Just IP doing what it was always capable of doing, in markets the company hadn’t yet entered.
The Difference Between Royalty Income and Every Other Revenue Line
Here’s what founders who discover licensing royalties consistently tell me: it doesn’t feel like the revenue they’re used to. There’s no sales call to close. No customer to onboard. No support ticket to resolve. The royalty arrives because someone else is running a business using your IP.
That’s not passive income in the lazy sense. Building the IP, identifying the right licensees, structuring the deal, and maintaining the relationship all take real work. But once a licensing agreement is signed and operating, the marginal cost of that revenue is close to zero.
Licensing and royalty financing is one of the most overlooked examples of non-dilutive funding available to startups — distinct from grants, debt, and equity in that it generates revenue from assets the company already owns rather than requiring new capital or obligations.
Investors see it the same way. Royalty income sits differently on your financials than product revenue. It signals that your IP is real, defensible, and commercially validated. It carries a higher quality multiple. And it tells the story that your technology is worth paying for — in a way that no pitch deck slide ever quite does.
Where to Start: The 30-Day IP Revenue Assessment
If you want to know whether your startup is sitting on licensable IP, here’s the fastest path to an answer:
Week 1: List every asset your company owns that creates competitive advantage — patents (granted or pending), trade secrets, proprietary algorithms, datasets, processes, brand elements, and content. Don’t filter yet. Just list.
Week 2: For each asset, ask: who outside our current customer base would benefit from having access to this? Include adjacent industries, different geographies, and companies at different points in the value chain.
Week 3: For the top three to five candidates, ask: what would it cost them to build this themselves, and how long would it take? If the answer is “significant cost and more than 12 months,” you have a licensing conversation worth having.
Week 4: Identify the right contact at each target company. This is almost never the legal department. It’s the head of product, the VP of R&D, or the business development lead. Those are the people who buy IP access because they need a capability, not because they’re managing a legal risk.
At the end of 30 days, you’ll know whether your IP has licensing potential — and have a short list of companies worth approaching.
Ready to Find Out What Your IP Is Worth?
This is the work we do at LCG with startups who want to understand whether their IP can generate revenue independent of their product sales. We help you identify what’s licensable, map the right targets, and structure deals that generate real recurring income.
If you want to spend 15 minutes talking through your specific IP and whether a licensing strategy makes sense for where you are right now, schedule a free strategy call.
Ready to find out what your IP could be earning?
Schedule a free 15-minute strategy call with Rand Brenner. We’ll look at your IP, your industry, and whether there’s a licensing path worth pursuing.
Download the free 2026 IP Licensing Trends eBook — the seven market shifts shaping deals right now and how to position your IP to take advantage.
Stay in the Loop: The LCG Newsletter
Get Rand Brenner’s weekly insights on IP licensing strategy, deal structures, and what’s working in the market — delivered to your inbox. Written for IP owners and founders who want to turn their innovations into income.
Subscribe to the LCG Newsletter →
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.